These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12455577)

  • 1. Lymphocyte subset counts in CAPD patients in relation to administration of recombinant human erythropoietin and angiotensin-converting enzyme inhibitors.
    Grzegorzewska AE; Leander M
    Perit Dial Int; 2002; 22(5):625-8. PubMed ID: 12455577
    [No Abstract]   [Full Text] [Related]  

  • 2. Lymphocyte subset counts in continuous ambulatory peritoneal dialysis patients in relation to administration of recombinant human erythropoietin and angiotensin-converting enzyme inhibitors.
    Grzegorzewska AE; Leander M
    Adv Perit Dial; 2002; 18():6-11. PubMed ID: 12402577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal blood pressure.
    Krysiak R; Okopień B
    Pharmacol Rep; 2011; 63(5):1151-61. PubMed ID: 22180357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.
    MacFadyen RJ; Lees KR; Reid JL
    Br Heart J; 1991 Sep; 66(3):206-11. PubMed ID: 1657084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total and subset lymphocyte counts, angiotensin converting enzyme inhibitors, and dialysis duration in younger and older peritoneal dialysis patients.
    Leander M; Grzegorzewska AE; Karolewski M
    Adv Perit Dial; 2004; 20():190-3. PubMed ID: 15384824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Numerical and functional alterations in T and B lymphocyte subpopulations in CAPD patients treated with recombinant human erythropoietin].
    Tanabe R
    Nihon Jinzo Gakkai Shi; 1994 Oct; 36(10):1159-68. PubMed ID: 7815748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocytes subsets in the course of continuous ambulatory peritoneal dialysis (CAPD).
    Griveas I; Visvardis G; Fleva A; Papadopoulou D; Mitsopoulos E; Nikopoulos K; Manou E; Kyriklidou P; Ginikopoulou E; Meimaridou D; Pavlitou A; Sakellariou G
    Ren Fail; 2004 Nov; 26(6):641-6. PubMed ID: 15600255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers.
    Pratt MC; Lewis-Barned NJ; Walker RJ; Bailey RR; Shand BI; Livesey J
    Br J Clin Pharmacol; 1992 Oct; 34(4):363-5. PubMed ID: 1457271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The angiotensin converting enzyme inhibitors captopril and enalapril inhibit apomorphine-induced oral stereotypy in the rat.
    Banks RJ; Mozley L; Dourish CT
    Neuroscience; 1994 Feb; 58(4):799-805. PubMed ID: 8190257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE inhibitors do not affect erythropoietin efficacy in haemodialysis patients.
    Conlon PJ; Albers F; Butterly D; Schwab SJ
    Nephrol Dial Transplant; 1994; 9(9):1358. PubMed ID: 7816313
    [No Abstract]   [Full Text] [Related]  

  • 11. [Angiotensin-converting enzyme inhibitors as neutralizers of hydroxyl radical].
    Mira ML; Silva MM; Queirós MJ; Manso C
    Rev Port Cardiol; 1992 May; 11(5):425-30. PubMed ID: 1325814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease.
    Krysiak R; Sierant M; Marek B; Okopień B
    Endokrynol Pol; 2010; 61(6):683-90. PubMed ID: 21104642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antioxidant power of angiotensin-converting enzyme inhibitors in vitro.
    Benzie IF; Tomlinson B
    Br J Clin Pharmacol; 1998 Feb; 45(2):168-9. PubMed ID: 9491832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril.
    Essig J; Belz GG; Wellstein A
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):217S-223S. PubMed ID: 2548551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients?
    Hess E; Sperschneider H; Stein G
    Nephrol Dial Transplant; 1996 Apr; 11(4):749-751. PubMed ID: 8671881
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis.
    Fujimura A; Kajiyama H; Ebihara A; Iwashita K; Nomura Y; Kawahara Y
    Nephron; 1986; 44(4):324-8. PubMed ID: 3025754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
    Squire IB; MacFayden RJ; Reid JL; Devlin A; Lees KR
    J Cardiovasc Pharmacol; 1996 May; 27(5):657-66. PubMed ID: 8859935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of captopril and enalapril medication on the serum ACE test for sarcoidosis.
    Lieberman J; Zakria F
    Sarcoidosis; 1989 Sep; 6(2):118-23. PubMed ID: 2557660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of the angiotensin converting enzyme inhibitors captopril and enalapril on the conversion of procollagen to collagen.
    Männistö TK; Karvonen KE; Kerola TV; Ryhänen LJ
    J Hypertens; 2001 Oct; 19(10):1835-9. PubMed ID: 11593104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of captopril and enalapril, two angiotensin converting enzyme inhibitors, on immune reactivity in experimental lupus disease.
    Tarkowski A; Carlsten H; Herlitz H; Westberg G
    Agents Actions; 1990 Aug; 31(1-2):96-101. PubMed ID: 2285027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.